Tissue Regenix Group PLC (TRX) is acquiring CellRight Technologies, a US bone regeneration technology specialist, in a deal worth up to $30m. The acquisition is the first for Leeds, UK-based TRX and will significantly flesh out the company's portfolio – which has only one product being sold on the market – with 13 other products that are already being commercialized in North America and beyond.
TRX currently sells in the EU and US its DermaPure wound care product, which brought in revenue of £1.4m in 2016. The tissue scaffold is based on the firm's proprietary...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?